Re:What can mRNA treat next?
by dehrmann on Sunday May 02, 2021 @04:04PM
(#27018526)
Once drugs go off-patent, the subscription model is a lot less appealing. Even before then, allowing vaccines to sell for $200 per dose (I'm just making up this number) would encourage vaccine production. But you're right that this is an example of markets not doing the right thing, so it might take government, or even insurance company subsidies on vaccine development.
[ Parent
| on HN ]
That’s not an outlandish number; retail price of the HPV vaccine in developed countries is about 200 euro a dose (though in practice usually paid by health services). They get a lot cheaper once out of patent, of course.